2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1078
INDUSTRY
405
NIH
102
NETWORK
47
OTHER_GOV
31
FED
4
UNKNOWN
2
INDIV
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
42
Esophageal Neoplasms
24
Stomach Neoplasms
21
Rectal Neoplasms
15
Carcinoma, Non-Small-Cell Lung
14
Colorectal Neoplasms
12
Neoplasms
10
Brain Neoplasms
10
Triple Negative Breast Neoplasms
9
Lung Neoplasms
9
Small Cell Lung Carcinoma
8
Squamous Cell Carcinoma of Head and Neck
7
Neoplasm Metastasis
6
Esophageal Squamous Cell Carcinoma
6
Lymphoma, Large B-Cell, Diffuse
5
Carcinoma, Hepatocellular
5
Recurrence
4
Radiation Injuries
4
Nasopharyngeal Carcinoma
4
Melanoma
4
Lymphoma, Extranodal NK-T-Cell
4
Head and Neck Neoplasms
4
Uterine Cervical Neoplasms
3
Meningeal Carcinomatosis
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Hormone Receptor Positive Advanced Breast Cancer
3
HER2-positive Breast Cancer
3
Colonic Neoplasms
3
Vomiting
2
Interventions
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
UNKNOWN
×
Urinary Bladder Neoplasms
×
Clear all
NCT02346955
2020-08-27
MK-6018-001
KitovPharma
Phase 1
Terminated
27 enrolled
NCT03672240
2020-07-20
NMIBC
AsierisPharma
Phase 1/2
Completed
6 enrolled